Consensus ORPEA London S.E.

Stocks

Real-time Estimate Tradegate 02:25:10 16/10/2026 pm IST			5-day change	1st Jan Change
10.37 ^EUR	+2.29%		+2.97%	-29.38%

05/10	Emeis completes its exit from Latin America
05/10	Emeis Closes EUR111 Million Sale of Latin American Operations	MT

062000f5.Z2k6pZDAqnkRDjEOiapR4mN7UH8NANa6g51p0xsydrM.KVwPz-in3gx2TUFlvZooriUDZxRZapHLwd4L5nMCGtQiE13G_5POECM7Qg~ab8ac52d590015501e4c9742570fc41a

03/08	Emeis: Operations confirmed as under control
31/07	Emeis: Strong semester: Moving the right way
28/04	Emeis holds firm with backing from TP Icap Midcap
09/04	Emeis: Pivot from firefighting to foundations
26/03	Limited 2026 energy impact; inflation remains in focus
04/03	AlphaValue/Baader Europe Lifts Emeis Rating as Operations Normalize; Estimates Revised on Preliminary FY25 Results	MT
03/03	Emeis: Opinion change, from Sell to Reduce
18/02	Emeis: Operational beat and deleveraging milestones tempered by cautious 2026 guidance
29/25/29	Emeis: Opinion change, from Sell to Reduce
29/25/29	Emeis: Good momentum expected to extend
30/25/30	Emeis: Oddo BHF raises its target price
24/25/24	Emeis: Integrating the latest strategic real-estate partnership
04/25/04	Emeis: AlphaValue still a selller
04/25/04	Emeis: Encouraging updates in asset disposals
04/25/04	Emeis: Opinion change, from Sell to Reduce
22/25/22	Emeis: Justifying disposal progress is key
13/25/13	Emeis: Opinion change, from Sell to Add
07/25/07	Emeis: FY24: on the right track
20/24/20	Emeis: Opinion change, from Buy to Add
13/24/13	Emeis: Positive Q3 lifted by a pricing and occupancy recovery; asset sales well on-track
05/24/05	Emeis: Farewell to profit warnings (?)
03/24/03	Emeis: Target cut by -32.9%
29/24/29	Emeis: Profit warning again (and again)
04/24/04	Orpea: Integrating the detailed FY23 figures
15/24/15	Orpea: Challenging recovery in France, adequate elsewhere

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
ORPEA	-	-	-	-
CVS HEALTH CORPORATION				+24.74%
HCA HEALTHCARE, INC.				-1.69%
NATERA, INC.				-0.22%
QUEST DIAGNOSTICS INCORPORATED				+5.12%
LABCORP HOLDINGS INC.				+6.17%
TENET HEALTHCARE CORPORATION				+3.7%
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY				+19.97%
REDE D'OR SÃO LUIZ S.A.				+14.64%
IHH HEALTHCARE				+28.23%
Average				+11.18%
Weighted average by Cap.				+10.49%